This Is MS Multiple Sclerosis Community: Knowledge & Support

**Posted:** Wed May 11, 2005 6:36 am

OK, techinically this trial is for ulcerative colitis, but they mention that their pre-clinical work suggested a number of potential targets for this drug, including MS...plus it's a monoclonal antibody and those are attracting a lot of attention these days, so I thought it was worth posting.

Medarex Announces Phase I Clinical Trial of MDX-1100, a Fully Human Anti-IP10 Antibody, for the Treatment of Ulcerative Colitis

May 11, 2005 - PRNewswire-FirstCall - Medarex, Inc. today ...

**Posted:** Tue May 03, 2005 9:56 am

Dear all,

The Boston Cure Project site has posted an article today about Tovaxin - a T Cell vaccine. An individual provides details of his success with this treatment. Does anyone have any more information on this treatment - looks promising?

Bromley

http://www.bostoncure.org:8080/article. ... ode=nested

It's interesting how those treatments which stop attacks (Campath and Tovaxin), rather than just reduce attacks (the CRAB drugs only reduce the attacks by ...

**Posted:** Mon May 02, 2005 7:19 pm

Hi all

A Phase II Study of Atorvastatin (aka Lipitor) is now recruiting people across the US who have been diagnosed with Clinically Isolated Syndrome (CIS) and are at Risk for Multiple Sclerosis.

The definition of CIS, eligibility criteria and locations of centers recruiting people may be found here.

The study hypothesis states:

Quote:

Early intervention with atorvastatin in patients with CIS will result in a state of immunological tolerance.

The eventual findings should be ...

**Posted:** Fri Apr 08, 2005 7:19 am

Found this on the internet.

OxyPharma Announces Selection of Multiple Sclerosis (MS) Drug Development Candidate

STOCKHOLM, Sweden, April 5, 2005--Swedish drug development company OxyPharma has selected a candidate drug (CD) for the treatment of multiple sclerosis (MS) from its autoimmune diseases drug discovery program. The selected compound, Rob 895, is now ready to go into a full-scale pre-clinical program.

Rob 895 has been developed from OxyPharma's patented lead compound B-220, from which OxyPharma has developed ...

**Posted:** Tue Apr 05, 2005 9:13 am

It's only completed phase I so far...

4SC SUCCESSFULLY CONCLUDES PHASE I STUDY FOR PRODUCT CANDIDATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES

24 March 2005 - 4SC AG, a drug discovery and development company specialising in research and development of therapeutic agents, announced today that they have successfully concluded phase I studies for the small molecule product candidate SC12267 for treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
A safe and well ...

**Posted:** Mon Mar 28, 2005 3:51 pm

WWW.MULTIPLESCLEROSISBLUES.COM
IS A WEB PAGE I CREATED AS AN ATTEMPT TO REACH PEOPLE WHO HAVE HAD SEVERE (OR ANY FORM) OF INJECTION SITE LIPOATROPHY OR BAD PITTING AND DENTS. I HAVE TRIED ON MY OWN FOR TWO YEARS TO DEAL WITH TEVA NEUROSCIENCES AND HAVE STRUCK OUT.
THIS IS MY LAST HOPE.
PLEASE PLEASE VISIT THE PAGE, AND IF YOU CAN, CONTACT ME AND SHARE YOUR STORIES.
MY MOST ...

**Posted:** Tue Mar 22, 2005 2:28 pm

It took them quite a long time to publish, but better late than never I suppose...

Teva and Active Biotech Announce That Laquinimod Phase II Data Has Been Published Today in Neurology

BUSINESS WIRE - March 22, 2005 - Teva Pharmaceutical Industries and Active Biotech announced today that the final report of the Phase II study of laquinimod, which was successfully concluded in September 2003, has been published today in NEUROLOGY:

"Treatment with laquinimod reduces ...

**Posted:** Fri Mar 11, 2005 1:24 am

Clinical Trial Information for MBP8298

Protocol:
A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis
Description:
This is a two-year, randomized, double-blind, placebo-controlled, parallel-group trial in secondary progressive MS patients, comparing the time to confirmed worsening of disability as measured by EDSS (Expanded Disability Status Scale).

The trial is expected to enroll up to 553 patients. Patients will be administered either MBP8298 or ...

**Posted:** Mon Feb 14, 2005 8:39 pm

Still early days on this one, but the more the merrier...

PharmaFrontiers...Key Clinical Milestones in Multiple Sclerosis

THE WOODLANDS, Texas, Feb. 14, 2005 (PRIMEZONE) -- Cell therapy developer PharmaFrontiers Corp. (OTCBB:PFTR) has...reached critical milestones in two Phase I/II clinical trials to evaluate the application of its T Cell therapy in multiple sclerosis.

Two clinical studies of its Tovaxin autologous T Cell therapy for treatment of multiple sclerosis have reached critical milestones. In one study, a ...

**Posted:** Thu Feb 10, 2005 3:11 am

Whilst MS is not specifically mentioned in this release the fact that Serono are involved makes it very likely

Quote:

19 January 2005 Vernalis Plc: Anti-Inflammatory Compound Partnered with Serono Starts Clinical Trials Vernalis plc (LSE:VER, Nasdaq: VNLS), today announced that its partner Serono (virt-x: SEO and NYSE: SRA) has started a phase I clinical trial of a selective inhibitor of MMP-12 (matrix metalloprotease inhibitor-12). This is the first compound to enter the clinic resulting from ...

This Is MS Multiple Sclerosis Community: Knowledge & Support

News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

Last 10 active topics

General Discussion

Chiropractic Treatment

Chronic Cerebrospinal Venous Insufficiency (CCSVI)

Tysabri (Antegren or Natalizumab)

Copaxone

Login

Statistics

Statistics
	Total posts 203164 \| Total topics 20419 \| Total members 12690